Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicines For Europe Calls For Security Of Supply Legislation

Increasing Inflation And Potential Price Cuts May Otherwise Impede Access

Executive Summary

Medicines for Europe has urged the European Commission to enshrine security of supply considerations for essential medicines into legislature. Without these, additional cost containment measures for off-patent medicines under consideration by member states may ultimately threaten access by making production unsustainable for manufacturers.

You may also be interested in...

Medicines For Europe And European Commission Aligned On Energy Rationing

Medicines for Europe has urged the European Commission to exempt pharmaceutical suppliers, particularly those of biologic and antibiotic medicines, from any perspective energy rationing in the region, in line with new public guidelines.

Medicines For Europe Urges Intervention In Inflation Crisis

Medicines for Europe has called for alterations to regulations concerning the off-patent drug sector, which it says will allow the industry to respond more effectively to the region’s dramatic rise in inflation.

German Tamoxifen Shortage Shows Consequences Of Cost Containment

Supply issues around breast cancer treatment tamoxifen in Germany demonstrate the damaging effects of European cost-containment measures, Medicines for Europe has warned, citing an “urgent need to revise unsustainable pricing and tendering policies.”

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts